Trastuzumab-dkst is the first biosimilar approved in the US for treating breast cancer or stomach cancer and the second biosimilar approved in the US for the treatment of cancer.
The FDA has approved the first biosimilar for the treatment of certain breast and stomach cancers, according to a press release from the administration.
Mylan GmbH’s trastuzumab-dkst (Ogivri) has been approved as a biosimilar to trastuzumab (Herceptin) for patients with breast or metastatic stomach cancer whose tumors overexpress the HER2 gene.
“The FDA continues to grow the number of biosimilar approvals, helping to promote competition that can lower health care costs. This is especially important when it comes to diseases like cancer, that have a high cost burden for patients,” said FDA Commissioner Scott Gottlieb, MD, in the statement. “We’re committed to taking new policy steps to advance our biosimilar pathway and promote more competition for biological drugs.”
According to the FDA, the approval of trastuzumab-dkst comes after a review of evidence that included:
Common side effects of trastuzumab-dkst for the treatment of HER2+ breast cancer include headache, diarrhea, nausea, congestive heart failure, insomnia, and infection. Common side effects of the biosimilar for the treatment of HER2+ metastatic stomach cancer include neutropenia, stomatitis, low levels of blood platelets, and anemia.
Like trastuzumab, the labeling for trastuzumab-dkst includes a boxed warning to advise healthcare professionals and patients about the increased risk for heart disease, infusion reactions, lung damage, and harm to a developing fetus.
Trastuzumab-dkst is the first biosimilar approved in the US for treating breast cancer or stomach cancer and the second biosimilar approved in the US for the treatment of cancer.
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More